Prof. Dr. Xuehao Wang, MD

Academician of the Chinese Academy of Engineering, director of the Institute of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Dr. Prof. Wang received his medical master degree from Nanjing Medical University in 1982. He was trained on liver surgery in the University of Pittsburgh-Pittsburgh between September 1983 and October 1985.

Dr. Prof. Wang is an Academician of the Chinese Academy of Engineering, Professor (grade A), tutor of doctoral candidates, chief physician. Currently he is the director of the Institute of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, director of the clinical key discipline of organ transplantation of the National Health and Family Planning Commission (NHFPC), director of key laboratory, member of the human organ transplantation expert group, chief of the Group of Transplant Immunology, Chinese Medical Association, director of Liver Transplantation Center of Jiangsu Province, and vice president of Medical Association of Jiangsu Province. He is the member of the editorial boards of top journals including HBPT INT, WJG, Chinese Journal of Organ Transplantation, Chinese Journal of Digestive Surgery, and Chinese Journal of Bases and Clinics in General Surgery.

Dr. Wang is a pioneer in living donor liver transplantation (LDLT) in mainland China and also one of the few scholars who adopted LDLT in clinical practices worldwide. In mainland China, Dr. Wang for the first time established a standard technical system for LDLT and promoted this technique nationwide. His unremitting efforts paved the way for the wide adoption of LDLT.   His innovative insights about the basics and clinical application of living related liver donor transplantation for Wilson's disease bring new light to the surgical treatment of this disease. Early in June 1986, he was the first Chinese author that reported the role of hepatic artery angiography with iodinated oil in the diagnosis of liver cancer, which paved the way for the modern interventional treatment for liver cancer in China. In November 2012, under his leadership and supervision, the resected liever specimens carrying hemangioma, which had been discarded in conventional practices, were transplanted into liver cancer patients, and the outcomes were quite good. This attempt provided new insight for the maximal use of marginal liver in liver transplantation. In recent years, he has carried out or completed 4 research projects supported by the National Natural Science Fund and/or National "Eighth Five-year" Science and Technology Research Program, over 30 projects supported by provincial or ministerial research funds, and over 30 projects supported by the provincial health authorities or the Nanjing Medical University. The overall grants exceed 20 million RMB yuan. As the principal investigator, he was the winner of one National Scientific and Technological progress Award (second prize), one Jiangsu Provincial Science and Technology Progress Award (first prize), and six provincial or ministerial research awards (second prizes). His honorable titles included "National Health System Excellent Worker", "Norman Bethune-style Medical Staff", "Advanced Worker", and "Nanjing 's City Hero in Science and Technology". He was the winner of the "Award for Outstanding Contributions in Medicine" and the "Jiangsu Province Outstanding Medical Award". In 2015, he won the noble title of "National Advanced Worker". He has obtained 3 invention patents. He has published over 400 scientific articles, among which 85 were published in SCI-indexed journals (as the first author or corresponding author). He is the editor, deputy editor, or contributor of 20 monographs. Among his students, 1 has been titled as the Cheung Kong Scholar, 1 was the winner of the National Outstanding Youth Fund, 1 was listed in the Jiangsu Province Leading Talents and 5 as Key Talents, 10 were listed in the Jiangsu Province 333 Engineering Talents, and 11 were listed as the Peak Talents in Six Key Disciplines.

Prof. Dr. Jianxing He, MD, FACS

Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Professor He is the Director and Professor of the Thoracic Surgery Department, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Diseases (GIRD), as well as the President of the First Affiliated Hospital of Guangzhou Medical University, China. He completed his medical studies at Guangzhou Medical University, and attained a higher research doctorate in thoracic surgery at the Guangdong Institute of Cardiovascular Disease while concurrently acting as the Deputy Director of the Thoracic Surgery Department of Guangzhou Medical University. Professor He later became a Fellow of the American College of Surgeons. His has the world-largest clinical experience in video-assisted thoracic surgery and non-intubation minimally invasive thoracic surgery. His other appointments include being the Primary Investigator of the National Key Laboratory of Respiratory Disease, Chief Advisor of National Ministry of Health Clinical Invasive Pathway Technique Advisory Board, Chairman of National Evaluation Committee for Endoscopic Skills, President of Guangdong Thoracic Surgeon Society, Chief Physician and Director of the thoracic surgery department of the First Hospital Affiliated to Guangzhou Medical University, and Primary Investigator of Translational Medicine Lab in the First Affiliated Hospital of Guangzhou Medical University. Professor He has published more than 200 scientific papers in thoracic surgery, including a seminal paper published in Lancet regarding a molecular assay he developed to predict survival in resected non-squamous, non-small-cell lung cancer. He also established the Asian-Pacific Lung Cancer Specimen and Tissue Bank, which has collected more than 20,000 samples including 18 multi-resisted lung cancer cell lines. Professor He has an extensive and impressive array of research experience, currently undertaking more than 30 scientific projects supported by National 863 Program and National Science Foundation.

Prof. Dr. Rafael Rosell, MD, PhD

Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, Badalona (Barcelona), Spain

Dr. Rafael Rosell is Director of the Cancer Biology and Precision Medicine Programat the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona, Barcelona, Spain), Chief Scientific Officer, Chairman and Founder of Pangaea Biotech SL (Barcelona), Chief Medical Officer and President of the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital (Barcelona) and Founder and President of the Molecular Oncology Research Foundation (Barcelona). He is Founder and Director of International Relations and Projects, Spanish Lung Cancer Group (SLCG) and a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP).

Dr. Rosell’s contributions to translational medical oncology, with particular emphasis on the field of non-small-cell lung cancer with EGFR mutations, have earned him international recognition: in 2013he was recognized by The Lancet as the highest authority in lung cancer in Europe; he received the Raymond Bourgine Award from the International Congress on Anti-Cancer Treatment (ICACT) for contributions to cancer research in 2012;in 2011 he was honored by the European Society of Medical Oncology (ESMO) withthe Hamilton Fairley Award for lifetime achievements in science and clinical/laboratory research, and in 2008 the Bonnie J. Addario Lung Cancer Foundation presented him with the “Asclepios” Award to pioneers in research. DrRosell has also been named Professor Honoris Causa by the University of Cordoba in Argentina, Eminent Clinical Scholarin Residence by the Winship Cancer Institute, Emory University School of Medicine, Georgia, USA, and awarded the Silver Caravel by the city of Bari,Italy in recognition of his work in lung cancer.

The innovative work of Dr.Rosell’s multidisciplinary team has long focused on the design and selection of personalized cancer treatments based on genetic analysis and characterization of each patient’s tumor in order to optimize outcomes to treatment.Investigations center on characterization of new genes involved in the development of cancer and resistance to targeted therapies. Among others, the group has performed groundbreaking analyses of EGFR, KRAS and ALK as well as RNA expression analysis of multiple genes such as BRCA1, AEG1 and RAP80,demonstrating significant improvements in response to targeted treatments. Inthe field of lung cancer in particular they have achieved special recognition for their investigations in neoadjuvant chemotherapy, demonstrating a survival benefit in locally advanced lung cancer, as well as in metastatic patients.

Dr. Rosell has authored over600 articles published in peer-reviewed medical and scientific journals, and he has given more than 800 presentations at medical and scientific conferences around the world. He is Editor-in-Chief ofT ranslational Lung Cancer Research, Associate Editor for Clinical Lung Cancer and is on the Editorial Board of several professional journals, including Annals of Oncology, Clinical Cancer Research and Future Oncology. He is past president of the Asociación Espanola de Investigación sobre el Cancer (ASEICA) and past editor of Revista de Oncología, the official publication of five Spanish oncology societies. 

Dr. Rosell is a member of the International Association for the Study of Lung Cancer (IASLC) and was Scientific Chair of their 2005 World Conference on Lung Cancer.  He is an active member of the Protocol Review Committee of the European Organization for Research and Treatment of Cancer(EORTC), and serves on the Scientific Program Sub-Committee (non-small-cell lung cancer, metastatic) for the annual congress of the European Medical Oncology Society (ESMO). He was Scientific Chair of the 1st& 2ndEuropean Lung Cancer Congress jointly sponsored by IASLC and ESMO. He also participated in the ASCO Scientific Programs Committee from 2002 through 2004.